Literature DB >> 22692741

First report of an extensively drug-resistant VIM-2 metallo-β-lactamase-producing Brevundimonas diminuta clinical isolate.

Marisa N Almuzara1, Claudia M Barberis, Carlos H Rodríguez, Angela M R Famiglietti, Maria S Ramirez, Carlos A Vay.   

Abstract

In the literature, only three Brevundimonas diminuta environmental isolates carrying metallo-β-lactamase genes were recently published. However, so far, no B. diminuta clinical isolates carrying these carbapenem resistance genes have been described. Here we report the first VIM-2 metallo-β-lactamase-producing B. diminuta clinical isolate obtained from an immunocompromised patient.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22692741      PMCID： PMC3421493          DOI： 10.1128/JCM.00924-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  First isolation of blaVIM-2 in an environmental isolate of Pseudomonas pseudoalcaligenes.

Authors:  Sandra Quinteira; Helena Ferreira; Luísa Peixe
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

2.  16S ribosomal DNA amplification for phylogenetic study.

Authors:  W G Weisburg; S M Barns; D A Pelletier; D J Lane
Journal:  J Bacteriol       Date:  1991-01       Impact factor: 3.490

3.  Brevundimonas diminuta keratitis.

Authors:  Rahul T Pandit
Journal:  Eye Contact Lens       Date:  2012-01       Impact factor: 2.018

4.  Brevundimonas diminuta infections and its resistance to fluoroquinolones.

Authors:  Xiang Y Han; Roberto A Andrade
Journal:  J Antimicrob Chemother       Date:  2005-05-09       Impact factor: 5.790

5.  Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.

Authors:  L Poirel; T Naas; D Nicolas; L Collet; S Bellais; J D Cavallo; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum beta-lactamases in a Klebsiella pneumoniae clinical strain isolated in Argentina.

Authors:  Roberto Melano; Alejandra Corso; Alejandro Petroni; Daniela Centrón; Betina Orman; Adriana Pereyra; Noemí Moreno; Marcelo Galas
Journal:  J Antimicrob Chemother       Date:  2003-05-29       Impact factor: 5.790

7.  Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp.

Authors:  K Lee; Y S Lim; D Yong; J H Yum; Y Chong
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

8.  First isolation of two colistin-resistant emerging pathogens, Brevundimonas diminuta and Ochrobactrum anthropi, in a woman with cystic fibrosis: a case report.

Authors:  Magalie Menuet; Fadi Bittar; Nathalie Stremler; Jean-Christophe Dubus; Jacques Sarles; Didier Raoult; Jean-Marc Rolain
Journal:  J Med Case Rep       Date:  2008-12-05

9.  First case of human infection due to Pseudomonas fulva, an environmental bacterium isolated from cerebrospinal fluid.

Authors:  Marisa N Almuzara; Miryam Vazquez; Naoto Tanaka; Marisa Turco; Maria S Ramirez; Eduardo L Lopez; Fernando Pasteran; Melina Rapoport; Adriana Procopio; Carlos A Vay
Journal:  J Clin Microbiol       Date:  2009-12-23       Impact factor: 5.948

10.  VIM-2-producing Pseudomonas putida, Buenos Aires.

Authors:  Marisa Almuzara; Marcela Radice; Natalia de Gárate; Alejandra Kossman; Arabela Cuirolo; Gisela Santella; Angela Famiglietti; Gabriel Gutkind; Varolos Vay
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883
View more
  1 in total

Review 1.  Brevundimonas spp: Emerging global opportunistic pathogens.

Authors:  Michael P Ryan; J Tony Pembroke
Journal:  Virulence       Date:  2018-01-01       Impact factor: 5.882
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.